Raymond James Financial
FHTX icon

Raymond James Financial’s Foghorn Therapeutics FHTX Stock Holding History

Raymond James Financial’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Buy
2,602,382
+96,561
+4% +$530K ﹤0.01% 1834
2025
Q4 		$13.5M Buy
2,505,821
+43,333
+2% +$196K ﹤0.01% 1731
2025
Q3 		$12M Buy
2,462,488
+95,196
+4% +$505K ﹤0.01% 1774
2025
Q2 		$11.1M Buy
2,367,292
+148,940
+7% +$622K ﹤0.01% 1783
2025
Q1 		$8.1M Buy
2,218,352
+188,969
+9% +$861K ﹤0.01% 1984
2024
Q4 		$9.58M Buy
+2,029,383
New +$14.8M ﹤0.01% 1883

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's FHTX Position: Q1 2026 in Review

Raymond James Financial increased its Foghorn Therapeutics (FHTX) stake by 3.9% in Q1 2026, buying an estimated $530K and bringing the position to 2,602,382 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Raymond James Financial first reported a position in FHTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $13.5M in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Raymond James Financial held 2,602,382 shares of Foghorn Therapeutics worth $12.4M as of Q1 2026.
  • Raymond James Financial bought 96,561 Foghorn Therapeutics shares in Q1 2026, an estimated $530K.
  • Foghorn Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #1834 holding.
  • Raymond James Financial first reported a position in Foghorn Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Foghorn Therapeutics position peaked at $13.5M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.